A Multicenter, Double Blind, Placebo-Controlled Study of Pepto-Bismol (Bismuth Subsalicylate) on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral TECFIDERA (Dimethyl Fumarate) Delayed-Release Capsules Twice Daily

Trial Profile

A Multicenter, Double Blind, Placebo-Controlled Study of Pepto-Bismol (Bismuth Subsalicylate) on Gastrointestinal Tolerability in Healthy Volunteers Receiving Oral TECFIDERA (Dimethyl Fumarate) Delayed-Release Capsules Twice Daily

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Jun 2015

At a glance

  • Drugs Dimethyl fumarate (Primary) ; Bismuth salicylate
  • Indications Gastrointestinal disorders; Multiple sclerosis
  • Focus Therapeutic Use
  • Sponsors Biogen Idec
  • Most Recent Events

    • 28 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
    • 21 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 21 Nov 2013 Planned number of patients changed from 176 to 175 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top